Skip to main content
SpringerLink
Log in

Erythropoese stimulierende Pharmaka (ESP)

  • Chapter
  • First Online:
Transfusionsassoziierte Pharmakotherapie

  • 2157 Accesses

Zusammenfassung

Die perioperative Therapie mit Erythropoese stimulierenden Pharmaka (ESP) zur Vermeidung von allogenen Bluttransfusionen vermeidet Komplikationen, verkürzt die Verweildauer, verringert die Wiederaufnahmerate und ist kostendeckend, wenn sie differenziert als individuelles Hämotherapiekonzept für den jeweiligen Patienten etabliert und eingesetzt wird. Sie kann nicht nur bei elektiven und bei lang vorgeplanten Operationen effektiv und sicher durchgeführt werden, sondern auch mit wesentlich kürzerer Vorbereitungszeit, und ist, wie uns die Fallberichte der Zeugen Jehovahs lehren, auch eine zusätzliche Option bei Notfalleingriffen. Sie ist sicher und unbedenklich, wenn die Pharmakologie der ESP sowie der Hämoglobin-Indikationsbereich von 10–13 g/dL beachtet und eine medikamentöse Thromboseprophylaxe durchgeführt werden. Nicht empfohlen ist sie als generelles Programm für jeden Patienten, für die Anämie beim kritisch Kranken auf der Intensivstation und bei der Anämie des Frühgeborenen. Die Evidenzlage für die einzelnen in diesem Kapitel gegebenen Daten wird aus der 2015/2016 zu erwartenden AWMF Leitlinie ’präoperative Anämie’ klar ersichtlich sein.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  1. Lin DM, Lin ES, Tran MH. Efficacy and safety of erythropoietin and intravenous iron in perioperative blood management: a systematic review. Transfusion medicine reviews, 27: 221–234, 2013

    Google Scholar 

  2. Beattie WS, Karkouti K, Wijeysundera DN, Tait G. Risk associated with preoperative anemia in noncardiac surgery: a single-center cohort study. Anesthesiology, 110: 574–581, 2009

    Article  PubMed  Google Scholar 

  3. Carson JL, Noveck H, Berlin JA, Gould SA. Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion. Transfusion, 42: 812–818, 2002

    Article  PubMed  Google Scholar 

  4. Hebert PC, Carson JL. Transfusion threshold of 7 g per deciliter–the new normal. The New England journal of medicine, 371: 1459–1461, 2014

    Article  PubMed  Google Scholar 

  5. Carson JL, Sieber F, Cook DR et al. Liberal versus restrictive blood transfusion strategy: 3-year survival and cause of death results from the FOCUS randomised controlled trial. Lancet, 385: 1183–1189, 2014

    Google Scholar 

  6. Carson JL, Hebert PC. Should we universally adopt a restrictive approach to blood transfusion? It's all about the number. The American journal of medicine, 127: 103–104, 2014

    Article  PubMed  Google Scholar 

  7. Shander A, Javidroozi M, Naqvi S, Aregbeyen O, Caylan M, Demir S, Juhl A. An update on mortality and morbidity in patients with very low postoperative hemoglobin levels who decline blood transfusion (CME). Transfusion, 54: 2688-2695; quiz 2687, 2014

    Google Scholar 

  8. Jo KI, Shin JW, Choi TY, Park YJ, Youm W, Kim MJ. Eight-year experience of bloodless surgery at a tertiary care hospital in Korea. Transfusion, 53: 948–954, 2013

    Article  PubMed  Google Scholar 

  9. Bretagnol A, Tamburini J, Guedj M, Denier C, Pene F. Profound anaemia and acute blindness in a Jehovah's Witness. Lancet, 382: 998, 2013

    Article  PubMed  Google Scholar 

  10. Musallam KM, Tamim HM, Richards T, et al. Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. Lancet, 378: 1396–1407, 2011

    Article  PubMed  Google Scholar 

  11. Jelkmann W. Physiology and pharmacology of erythropoietin. Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 40: 302–309, 2013

    Google Scholar 

  12. Lorentz A, Eckardt KU, Osswald PM, Kruse C. Perioperative plasma erythropoietin levels in hip arthroplasty. Annals of hematology, 68: 117–124, 1994

    Article  CAS  PubMed  Google Scholar 

  13. Nogueras S, Merino A, Ojeda R, Carracedo J, Rodriguez M, Martin-Malo A, Ramirez R, Aljama P. Coupling of endothelial injury and repair: an analysis using an in vivo experimental model. American journal of physiology Heart and circulatory physiology, 294: H708–713, 2008

    Article  CAS  PubMed  Google Scholar 

  14. Hirata Y, Nagata D, Suzuki E, Nishimatsu H, Suzuki J, Nagai R. Diagnosis and treatment of endothelial dysfunction in cardiovascular disease. International heart journal, 51: 1–6, 2010

    Article  CAS  PubMed  Google Scholar 

  15. Fliser D, Bahlmann FH. Erythropoietin and the endothelium - a promising link? Eur J Clin Invest, 38: 457–461, 2008

    Article  CAS  PubMed  Google Scholar 

  16. Frietsch T. Wirkungen systemischer und zerebraler Erythropoetin-Überexpression : Untersuchungen an transgenen Mäusen und an Ratten. Heidelberg, Univ., Habil.-Schr., 2003, 2002 pp 95 Bl

    Google Scholar 

  17. Wang L, Di L, Noguchi CT. Erythropoietin, a novel versatile player regulating energy metabolism beyond the erythroid system. International journal of biological sciences, 10: 921–939, 2014

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Sinclair AM, Coxon A, McCaffery I et al. Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood, 115: 4264–4272, 2010

    Article  CAS  PubMed  Google Scholar 

  19. Elliott S, Busse L, Swift S, McCaffery I, Rossi J, Kassner P, Begley CG. Lack of expression and function of erythropoietin receptors in the kidney. Nephrology Dialysis Transplantation, 27: 2733–2745, 2012

    Article  CAS  Google Scholar 

  20. Scott CL, Robb L, Papaevangeliou B, Mansfield R, Nicola NA, Begley CG. Reassessment of interactions between hematopoietic receptors using common beta-chain and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with receptors for erythropoietin, granulocyte colony-stimulating factor, or stem cell factor. Blood, 96: 1588–1590, 2000

    CAS  PubMed  Google Scholar 

  21. Swift S, Ellison AR, Kassner P, McCaffery I, Rossi J, Sinclair AM, Begley CG, Elliott S. Absence of functional EpoR expression in human tumor cell lines. Blood, 115: 4254–4263, 2010

    Article  CAS  PubMed  Google Scholar 

  22. Henke M, Laszig R, Rube C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet, 362: 1255–1260, 2003

    Article  CAS  PubMed  Google Scholar 

  23. Goodnough LT, Shander A Current status of pharmacologic therapies in patient blood management. Anesth Analg, 116: 15–34, 2013

    Article  CAS  PubMed  Google Scholar 

  24. Gimenez LF, Scheel PJ. Clinical application of recombinant erythropoietin in renal dialysis patients. In: Erythropoietin: Basic and Clinical Aspects. edited by SPIVAK, P. V., Philadelphia PA, WB Saunders, 1994, pp 913–932

    Google Scholar 

  25. Besarab A. Physiological and pharmacodynamic considerations for route of EPO administration. Seminars in nephrology, 20: 364–374, 2000

    Google Scholar 

  26. Besarab A, Amin N, Ahsan, M et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. Journal of the American Society of Nephrology : JASN, 11: 530–538, 2000

    CAS  PubMed  Google Scholar 

  27. Albaramki J, Hodson EM, Craig JC, Webster AC. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. The Cochrane database of systematic reviews, 1: Cd 007857, 2012

    Google Scholar 

  28. Besarab A, Reyes CM, Hornberger J. Meta-analysis of subkutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. American journal of kidney diseases : the official journal of the National Kidney Foundation, 40: 439–446, 2002

    Article  CAS  Google Scholar 

  29. Schmid H. Cost-effectiveness of continuous erythropoietin receptor activator in anemia. ClinicoEconomics and outcomes research : CEOR, 6: 319–330, 2014

    Google Scholar 

  30. Hahn D, Cody JD, Hodson EM. Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients. The Cochrane database of systematic reviews, 5: CD 003895, 2014

    Google Scholar 

  31. Besarab A, Goodkin DA, Nissenson AR. The normal hematocrit study–follow-up. The New England journal of medicine, 358: 433–434, 2008

    Article  CAS  PubMed  Google Scholar 

  32. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. The New England journal of medicine, 355: 2085–2098, 2006

    Google Scholar 

  33. Macdougall IC. CREATE: new strategies for early anaemia management in renal insufficiency. Nephrology Dialysis Transplantation, 18 Suppl 2: ii13–16, 2003

    Google Scholar 

  34. Mix TC, Brenner RM, Cooper ME et al. Rationale–Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. American heart journal, 149: 408–413, 2005

    Article  CAS  PubMed  Google Scholar 

  35. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. The New England journal of medicine, 316: 73–78, 1987

    Article  CAS  PubMed  Google Scholar 

  36. Goodnough LT, Price TH, Rudnick S, Soegiarso RW. Preoperative red cell production in patients undergoing aggressive autologous blood phlebotomy with and without erythropoietin therapy. Transfusion, 32: 441–445, 1992

    Article  CAS  PubMed  Google Scholar 

  37. Wittig M, Osswald PM, Lorentz A, Jani L. Deposit of autologous blood at short intervals. Anaesthesist, 43: 9–15, 1994

    Article  CAS  PubMed  Google Scholar 

  38. Singbartl G, Malgorzata S, Quoss A. Preoperative autologous blood donation - part II. Adapting the predeposit concept to the physiological basics of erythropoiesis improves its efficacy. Minerva anestesiologica, 73: 153–160, 2007

    Google Scholar 

  39. Goodnough LT, Verbrugge D, Marcus RE, Goldberg V. The effect of patient size and dose of recombinant human erythropoietin therapy on red blood cell volume expansion in autologous blood donors for elective orthopedic operation. Journal of the American College of Surgeons, 179: 171–176, 1994

    CAS  PubMed  Google Scholar 

  40. Agency EM. Epoetin Alfa Hexal. www, European Medicines Agency 2012 pp 3

    Google Scholar 

  41. Wolff M, Fandrey J, Hirner A, Jelkmann W. Perioperative use of recombinant human erythropoietin in patients refusing blood transfusions. Pathophysiological considerations based on 5 cases. European journal of haematology, 58: 154–159, 1997

    Article  CAS  PubMed  Google Scholar 

  42. Tomeczkowski J, Fritze J. Preoperative anaemia in major elective orthopedic surgery: efficacy, safety and cost-effectiveness. Anasthesiologie & Intensivmedizin, 52: 217–227, 2011

    Google Scholar 

  43. Kotze A, Carter LA, Scally AJ. Effect of a patient blood management programme on preoperative anaemia, transfusion rate, and outcome after primary hip or knee arthroplasty: a quality improvement cycle. British journal of anaesthesia, 108: 943–952, 2012

    Article  CAS  PubMed  Google Scholar 

  44. Delasotta LA, Rangavajjula A, Frank ML, Blair J, Orozco F, Ong A. The Use of Preoperative Epoetin-alpha in Revision Hip Arthroplasty. The open orthopaedics journal, 6: 179–183, 2012

    Article  PubMed Central  PubMed  Google Scholar 

  45. Delasotta LA, Rangavajjula AV, Frank ML et al. The Use of Epoetin-alpha in Revision Knee Arthroplasty. Advances in orthopedics, 2012: 595027, 2012

    Google Scholar 

  46. Tonia T, Mettler A, Robert N, Schwarzer G et al. Erythropoietin or darbepoetin for patients with cancer. The Cochrane database of systematic reviews, 12: Cd 003407, 2012

    Google Scholar 

  47. Devon KM, McLeod RS. Pre and peri-operative erythropoietin for reducing allogeneic blood transfusions in colorectal cancer surgery. The Cochrane database of systematic reviews: Cd 007148, 2009

    Google Scholar 

  48. Stowell CP, Jones SC, Enny C, Langholff W, Leitz G. An open-label, randomized, parallel-group study of perioperative epoetin alfa versus standard of care for blood conservation in major elective spinal surgery: safety analysis. Spine, 34: 2479–2485, 2009

    Article  PubMed  Google Scholar 

  49. Vinni Juneja M. Continuing Reassessment of the Risks of Erythropoiesis-Stimulating Agents (ESAs) in Patients with Cancer. In: FDA (Ed.) http://www.fda.gov/ohrms/dockets/ac/07/slides/2007-4301s2-07-FDA-Juneja_files/frame.htm - slide0214.htm, FDA, 2007

  50. Fergusson D. Management of perioperative anemia: Human Erythropoietin. In: GROUP, L. (Ed.) NATA 9th Annual Symposium Lisbon, Network for Advancement of Transfusion Alternatives, 2008

    Google Scholar 

  51. Rizzo JD, Brouwers M, Hurley P et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood, 116: 4045–4059, 2010

    Article  CAS  PubMed  Google Scholar 

  52. Suttorp MM, Hoekstra T, Ocak G et al. Erythropoiesis-stimulating agents and thrombotic events in dialysis patients. Thrombosis research, 134: 1081–1086, 2014

    Google Scholar 

  53. Glaspy J, Dunst J. Can erythropoietin therapy improve survival? Oncology, 67 Suppl 1: 5–11, 2004

    Article  Google Scholar 

  54. Goodnough LT, Shander A. Update on erythropoiesis-stimulating agents. Best practice & research Clinical anaesthesiology, 27: 121–129, 2013

    Google Scholar 

  55. Sienas L, Wong T, Collins R, Smith J. Contemporary Uses of Erythropoietin in Pregnancy: A Literature Review. Obstetrical & Gynecological Survey, 68: 594–602, 2013

    Article  Google Scholar 

  56. Jansen Cilaq GmbH. Fachinformation ERYPO. 2009

    Google Scholar 

  57. Manns BJ, Tonelli M. The New FDA Labeling for ESA—Implications for Patients and Providers. Clinical Journal of the American Society of Nephrology : CJASN, 7: 348–353, 2012

    Google Scholar 

  58. Ohlsson A, Aher SM. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. The Cochrane database of systematic reviews, 4: Cd 004863, 2014

    Google Scholar 

  59. Aher SM, Ohlsson A. Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. The Cochrane database of systematic reviews, 4: Cd 004868, 2014

    Google Scholar 

  60. Palmer SC, Saglimbene, V Craig, JC et al. Darbepoetin for the anaemia of chronic kidney disease. The Cochrane database of systematic reviews, 3: Cd 009297, 2014

    Google Scholar 

  61. Hämotherapie, I-IAKH: Musterempfehlung zum etablierten Off-Label-Use von EPO und EIsen im im Blutsparenden Konzept PBM (Patient Blood Management)). In: IAKH (Ed.) http://www.iakh.de/handreichungen/sonstiges, www, 2014

  62. Möllmann M. Erythropoietin–physiology and therapeutic potentialities. Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS, 27: 461–468, 1992

    Google Scholar 

  63. Hasegawa Y, Takamatsu J, Iwase T et al. Effects of recombinant human erythropoietin on thrombosis and fibrinolysis in autologous transfusion for hip surgery. Archives of orthopaedic and trauma surgery, 119: 384–387, 1999

    Article  CAS  PubMed  Google Scholar 

  64. Lorentz A, Eckardt KU, Osswald PM, Duchow JR. Erythropoietin in levels in patients depositing autologous blood in short intervals. Annals of hematology, 64: 281–285, 1992

    Article  CAS  PubMed  Google Scholar 

  65. Eckardt KU, Lorentz A, Kurtz A. Oxygen-dependent erythropoietin production: Basis for compensation of blood losses. In: [Contributions to Infusion Therapy; Homologous blood saving methods in surgical medicine]. edited by Schleinzer, W., Singbartl, G., 1993, pp 228–239

    Google Scholar 

  66. Lorentz A, Jendrissek A, Eckardt KU, Schipplick M, Osswald PM, Kurtz A. Serial immunoreactive erythropoietin levels in autologous blood-donors. Transfusion, 31: 650–654, 1991

    Article  CAS  PubMed  Google Scholar 

  67. Lorentz A. Concerning: Gesemann M, et al.: Association of erythropoiesis during autologous blood donation with initial hemoglobin concentration and length of donation period. Infusionsther Transfusionsmed 1999;26 : 353-359. Infusion Therapy and Transfusion Medicine-Infusionstherapie Und Transfusionsmedizin, 27: 157–157, 2000

    Google Scholar 

  68. Sowade O, Ziemer S, Sowade B et al. The effect of preoperative recombinant human erythropoietin therapy on platelets and hemostasis in patients undergoing cardiac surgery. The Journal of laboratory and clinical medicine, 129: 376–383, 1997

    Article  CAS  PubMed  Google Scholar 

  69. Heiss MM, Tarabichi A, Delanoff C et al. Perisurgical erythropoietin application in anemic patients with colorectal cancer: A double-blind randomized study. Surgery, 119: 523–527, 1996

    Article  CAS  PubMed  Google Scholar 

  70. Lorentz A, Jendrissek A, Eckardt KU, Schipplick M, Osswald PM, Kurtz A: Serial immunoreactive erythropoietin levels in autologous blood donors. Transfusion, 31: 650–654, 1991

    Article  CAS  PubMed  Google Scholar 

  71. Mollmann M, Lubbesmeyer HJ, von Bormann B, Friedrich M, Schleinzer W, Brodner G: Erythropoietin therapy during frequent autologous blood donations. Dose-finding study. Anaesthesist, 44: 624–630, 1995

    Article  CAS  PubMed  Google Scholar 

  72. Rosencher N, Ozier Y. Érythropoïétine en péri-opératoire. Transfusion Clinique et Biologique, 10: 159–164, 2003

    Article  CAS  PubMed  Google Scholar 

  73. Weisbach V, Skoda P, Rippel R, Lauer G, Glaser A, Zingsem J, Zimmermann R, Eckstein R. Oral or intravenous iron as an adjuvant to autologous blood donation in elective surgery: a randomized, controlled study. Transfusion, 39: 465–472, 1999

    Article  CAS  PubMed  Google Scholar 

  74. Rosencher N, Ozier Y. Peri-operative use of EPO. Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 10: 159–164, 2003

    Google Scholar 

  75. Goodnough LT, Marcus RE. Erythropoiesis in patients stimulated with erythropoietin: the relevance of storage iron. Vox sanguinis, 75: 128–133, 1998

    Article  CAS  PubMed  Google Scholar 

  76. Goodnough LT. The role of iron in erythropoiesis in the absence and presence of erythropoietin therapy. Nephrology Dialysis Transplantation, 17 Suppl 5: 14–18, 2002

    Google Scholar 

  77. Zarychanski R, Turgeon AF, McIntyre L, Fergusson DA. Erythropoietin-receptor agonists in critically ill patients: a meta-analysis of randomized controlled trials. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 177: 725–734, 2007

    Google Scholar 

  78. Napolitano LM, Fabian TC, Kelly KM et al. Improved survival of critically ill trauma patients treated with recombinant human erythropoietin. The Journal of trauma, 65: 85–297; discussion 297-289, 2008.

    Google Scholar 

  79. Goodnough LT, Maniatis A, Earnshaw P et al. Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines. British journal of anaesthesia, 106: 13–22, 2011

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  80. IAKH: Rote-Hand-Brief zu allen Eisen-Präparaten zur intravenösen Applikation: Risiko schwerer Überempfindlichkeitsreaktionen. In: Frietsch, T. (Ed.) wwwiakhde/nachrichten. http://www.Iakh.de, 2013

  81. Posluszny JA, Napolitano LM. How do we treat life-threatening anemia in a Jehovah's Witness patient? Transfusion, 54: 3026–3034, 2014

    Article  CAS  PubMed  Google Scholar 

  82. Heh-Foster AM, Naber M, Pai MP, Lesar TS. Epoetin in the 'untransfusable' anaemic patient: a retrospective case series and systematic analysis of literature case reports. Transfusion medicine (Oxford, England), 24: 204–208, 2014

    Article  CAS  Google Scholar 

  83. de Araujo Azi LM Lopes FM Garcia LV. Postoperative management of severe acute anemia in a Jehovah's Witness. Transfusion, 54: 1153–1157, 2014

    Article  Google Scholar 

  84. Beliaev AM, Marshall RJ, Smith W, Windsor JA. Mortality risk stratification in severely anaemic Jehovah's Witness patients. Internal medicine journal, 42: e1–3, 2012

    Google Scholar 

  85. Ball AM, Winstead PS. Recombinant human erythropoietin therapy in critically ill Jehovah's Witnesses. Pharmacotherapy, 28: 1383–1390, 2008

    Article  CAS  PubMed  Google Scholar 

  86. Corwin HL, Gettinger A, Pearl RG et al. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. Jama, 288: 2827–2835, 2002

    Article  CAS  PubMed  Google Scholar 

  87. Duby JJ, Erstad BL, Abarca J, Camamo JM, Huckleberry Y, Bramblett SN. Impact of delayed initiation of erythropoietin in critically ill patients. BMC blood disorders, 7: 1, 2007

    Google Scholar 

  88. Kanakaris NK, Petsatodis, G Chalidis, B et al. The role of erythropoietin in the acute phase of trauma management: evidence today. Injury, 40: 21–27, 2009

    Google Scholar 

  89. Jelkmann I, Jelkmann W. Impact of erythropoietin on intensive care unit patients. Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 40: 310–318, 2013

    Google Scholar 

  90. McIntyre L, Tinmouth AT, Fergusson DA. Blood component transfusion in critically ill patients. Current opinion in critical care, 19: 326–333, 2013

    Google Scholar 

  91. Diamond PT. Severe anaemia: implications for functional recovery during rehabilitation. Disability and rehabilitation, 22: 574–576, 2000

    Google Scholar 

  92. Halm EA, Wang JJ, Boockvar K et al. The effect of perioperative anemia on clinical and functional outcomes in patients with hip fracture. Journal of orthopaedic trauma, 18: 369–374, 2004

    Article  PubMed Central  PubMed  Google Scholar 

  93. Yoon J, Kim S, Lee SC, Lim H. Postoperative high-dose intravenous iron sucrose with low dose erythropoietin therapy after total hip replacement. The Korean journal of internal medicine, 25: 454–457, 2010

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  94. Ranucci M, La Rovere MT, Castelvecchio S et al. Postoperative anemia and exercise tolerance after cardiac operations in patients without transfusion: what hemoglobin level is acceptable? The Annals of thoracic surgery, 92: 25–31, 2011

    Article  PubMed  Google Scholar 

  95. Johnson RG, Thurer RL, Kruskall MS et al. Comparison of two transfusion strategies after elective operations for myocardial revascularization. The Journal of thoracic and cardiovascular surgery, 104: 307–314, 1992

    CAS  PubMed  Google Scholar 

  96. Foss NB, Kristensen MT, Jensen PS, Palm H, Krasheninnikoff M, Kehlet H. The effects of liberal versus restrictive transfusion thresholds on ambulation after hip fracture surgery. Transfusion, 49: 227–234, 2009

    Article  PubMed  Google Scholar 

  97. Cladellas M, Farre N, Comin-Colet J et al. Effects of preoperative intravenous erythropoietin plus iron on outcome in anemic patients after cardiac valve replacement. The American journal of cardiology, 110: 1021–1026, 2012

    Article  CAS  PubMed  Google Scholar 

  98. Yoo YC, Shim JK, Kim JC, Jo YY, Lee JH, Kwak YL. Effect of single recombinant human erythropoietin injection on transfusion requirements in preoperatively anemic patients undergoing valvular heart surgery. Anesthesiology, 115: 929–937, 2011

    Article  CAS  PubMed  Google Scholar 

  99. Hogan M, Klein AA, Richards T. The impact of anaemia and intravenous iron replacement therapy on outcomes in cardiac surgery. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 47: 218–226, 2015

    Article  Google Scholar 

  100. Ponikowski P, van Veldhuisen DJ, Comin-Colet J et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. European Heart J. 36: 657–668, 2014

    Google Scholar 

  101. Anker SD, Colet JC, Filippatos G et al. Rationale and design of Ferinject® Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. European journal of heart failure, 11: 1084–1091, 2009

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  102. Jelkmann W. Erythropoietin: back to basics. Blood, 115: 4151–4152, 2010

    Article  PubMed  Google Scholar 

  103. Ehrenreich H, Weissenborn K, Prange H et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke, 40: e647–656, 2009

    Article  CAS  PubMed  Google Scholar 

  104. Sargin D, Friedrichs H, El-Kordi A, Ehrenreich H. Erythropoietin as neuroprotective and neuroregenerative treatment strategy: comprehensive overview of 12 years of preclinical and clinical research. Best practice & research Clinical anaesthesiology, 24: 573–594, 2010

    Google Scholar 

  105. Fertrin KY, Lanaro C, Franco-Penteado CF et al. Erythropoiesis-driven regulation of hepcidin in human red cell disorders is better reflected through concentrations of soluble transferrin receptor rather than growth differentiation factor 15. American journal of hematology, 89: 385–390, 2014

    Article  CAS  PubMed  Google Scholar 

  106. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nature genetics, 46: 678–684, 2014

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  107. D'Anna MC, Roque ME. Physiological focus on the erythropoietin-hepcidin-ferroportin axis. Canadian journal of physiology and pharmacology, 91: 338–345, 2013

    Google Scholar 

  108. Creange A, Lefaucheur JP, Balleyguier MO, Galacteros F. Iron depletion induced by bloodletting and followed by rhEPO administration as a therapeutic strategy in progressive multiple sclerosis: a pilot, open-label study with neurophysiological measurements. Neurophysiologie clinique = Clinical neurophysiology, 43: 303–312, 2013

    Google Scholar 

  109. Sonnenberg FA, Gregory P, Yomtovian R, Russell LB, Tierney W, Kosmin M, Carson JL. The cost-effectiveness of autologous transfusion revisited: implications of an increased risk of bacterial infection with allogeneic transfusion. Transfusion, 39: 808–817, 1999

    Article  CAS  PubMed  Google Scholar 

  110. Tomeczkowski J, Stern S, Müller A, von Heymann C. Potential Cost Saving of Epoetin alfa in Elective Hip or Knee Surgery due to Reduction in Blood Transfusions and Their Side Effects: A Discrete-Event Simulation Model. PLoS ONE, 8, 2013

    Google Scholar 

  111. Coyle D, Lee KM, Fergusson DA, Laupacis A. Economic analysis of erythropoietin use in orthopaedic surgery. Transfusion medicine (Oxford, England), 9: 21–30, 1999

    Article  CAS  Google Scholar 

  112. Coyle D, Lee KM, Fergusson DA, Laupacis A. Cost effectiveness of epoetin-alpha to augment preoperative autologous blood donation in elective cardiac surgery. PharmacoEconomics, 18: 161–171, 2000

    Article  CAS  PubMed  Google Scholar 

  113. Marchetti M, Barosi G. Cost-effectiveness of epoetin and autologous blood donationin reducing allogeneic blood transfusions incoronary artery bypass graft surgery. Transfusion, 40: 673–681, 2000

    Article  CAS  PubMed  Google Scholar 

  114. Davies L, Brown TJ, Haynes S, Payne K, Elliott RA, McCollum C. Cost-effectiveness of cell salvage and alternative methods of minimising perioperative allogeneic blood transfusion: a systematic review and economic model. Health technology assessment (Winchester, England), 10: iii-iv, ix-x, 1-210, 2006

    Google Scholar 

  115. Singbartl G, Schleinzer W. Cost analysis of autologous transfusion methods–a study of 5,017 patients. Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS, 34: 350–358, 1999

    Google Scholar 

  116. So-Osman C, Nelissen RG, Koopman-van Gemert AW et al. Patient blood management in elective total hip- and knee-replacement surgery (Part 1): a randomized controlled trial on erythropoietin and blood salvage as transfusion alternatives using a restrictive transfusion policy in erythropoietin-eligible patients. Anesthesiology, 120: 839–851, 2014

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Anästhesie und Intensivmedizin, Diakonissenkrankenhaus Mannheim, Speyerer Str. 91-93, 68163, Mannheim, Deutschland

    Prof. Dr. med. Thomas Frietsch

Authors
  1. Prof. Dr. med. Thomas Frietsch
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Soltau, Germany

    Günter Singbartl

  2. Department of Anesthesiology, Milton S. Hershey Medical Center, Hershey, USA

    Kai Singbartl

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Frietsch, T. (2016). Erythropoese stimulierende Pharmaka (ESP). In: Singbartl, G., Singbartl, K. (eds) Transfusionsassoziierte Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-47258-3_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-47258-3_2

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-47257-6

  • Online ISBN: 978-3-662-47258-3

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation